Literature DB >> 7627976

Association of sialyl-Lewis(a) and sialyl-Lewis(x) with MUC-1 apomucin ina pancreatic cancer cell line.

J J Ho1, B Siddiki, Y S Kim.   

Abstract

We have shown previously that the mucins of the human pancreatic cancer cell line, SW1990, have both sialyl-Lewis(a) and sialyl-Lewis(x) carbohydrate ligands that are implicated in tumor cell metastasis. In the present study, we undertook to identify the protein core of these mucins. SW1990 mucins that carry sialyl-Lewis(a) and sialyl-Lewis(x) bound to the MUC1 peptide-specific mAb 139H2. Removal of most of the sialic acids from SW1990 mucins by neuraminidase greatly enhanced binding of two other MUC1 peptide specific antibodies, HMFG-2 and SM-3. After removal of sialic acids, most of the mucins rich in sialyl-Lewis(a) and sialyl-Lewis(x) oligosaccharides no longer bound to a DEAE-cellulose column at pH 8.0. These results indicate that at least part of the sialyl-Lewis(a) and sialyl-Lewis(x) in SW1990 cells is associated with the MUC1 polypeptide. Moreover, sialic acids play an important role in determining the net negative charge of sialyl-Lewis(a) and sialyl-Lewis(x) rich mucins and in obscuring MUC1 peptide regions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7627976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.

Authors:  Seema Chugh; Vinayaga S Gnanapragassam; Maneesh Jain; Satyanarayana Rachagani; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Biochim Biophys Acta       Date:  2015-08-28

Review 2.  Advances in biomarker research for pancreatic cancer.

Authors:  Kruttika Bhat; Fengfei Wang; Qingyong Ma; Qinyu Li; Sanku Mallik; Tze-Chen Hsieh; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

3.  Phage-display library selection of high-affinity human single-chain antibodies to tumor-associated carbohydrate antigens sialyl Lewisx and Lewisx.

Authors:  S Mao; C Gao; C H Lo; P Wirsching; C H Wong; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

4.  Alkali-catalyzed beta-elimination of periodate-oxidized glycans: a novel method of chemical deglycosylation of mucin gene products in paraffin embedded sections.

Authors:  J C Hong; Y S Kim
Journal:  Glycoconj J       Date:  2000-10       Impact factor: 2.916

Review 5.  Oligosaccharides and glycoconjugates in human milk: their role in host defense.

Authors:  D S Newburg
Journal:  J Mammary Gland Biol Neoplasia       Date:  1996-07       Impact factor: 2.673

6.  Diagnostic and prognostic biomarkers in pancreatic carcinoma.

Authors:  John J Liang; Eric T Kimchi; Kevin F Staveley-O'Carroll; Dongfeng Tan
Journal:  Int J Clin Exp Pathol       Date:  2008-04-12

7.  A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.

Authors:  J Wesseling; S W van der Valk; J Hilkens
Journal:  Mol Biol Cell       Date:  1996-04       Impact factor: 4.138

Review 8.  MUC1 in carcinoma-host interactions.

Authors:  K Denda-Nagai; T Irimura
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 3.009

9.  Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.

Authors:  Darragh P O'Brien; Neomal S Sandanayake; Claire Jenkinson; Aleksandra Gentry-Maharaj; Sophia Apostolidou; Evangelia-Ourania Fourkala; Stephane Camuzeaux; Oleg Blyuss; Richard Gunu; Anne Dawnay; Alexey Zaikin; Ross C Smith; Ian J Jacobs; Usha Menon; Eithne Costello; Stephen P Pereira; John F Timms
Journal:  Clin Cancer Res       Date:  2014-06-17       Impact factor: 12.531

10.  Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence.

Authors:  C Gu; T Oyama; T Osaki; J Li; M Takenoyama; H Izumi; K Sugio; K Kohno; K Yasumoto
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.